Vivos (RDGL) 10-K 18 Mar 24 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2023	Mar. 18, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	0-53497
Entity Registrant Name	VIVOS INC
Entity Central Index Key	0001449349
Entity Tax Identification Number	80-0138937
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	719 Jadwin Avenue
Entity Address, City or Town	Richland
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	99352
City Area Code	(509)
Local Phone Number	736-4000
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 36,693,047
Entity Common Stock, Shares Outstanding		389,894,033
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	5525
Auditor Name	Fruci & Associates II, PLLC
Auditor Location	Spokane, Washington

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash	$ 1,592,287	$ 1,706,065
Accounts receivable	7,000	11,000
Prepaid expense	10,837	25,671
Total Current Assets	1,610,124	1,742,736
TOTAL ASSETS	1,610,124	1,742,736
Current Liabilities:
Accounts payable and accrued expense	245,004	81,692
Total Current Liabilities	245,004	81,692
Total Liabilities	245,004	81,692
Commitments and contingencies
STOCKHOLDERS’ EQUITY
Common stock, par value, $0.001, 950,000,000 shares authorized, 387,894,033 and 362,541,528 issued and outstanding, respectively	387,894	362,541
Additional paid in capital - common stock	73,791,430	71,217,954
Accumulated deficit	(82,450,781)	(79,556,028)
Total Stockholders’ Equity	1,365,120	1,661,044
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	1,610,124	1,742,736
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Preferred stock value	2,071	2,071
Additional paid in capital	8,842,458	8,842,458
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Preferred stock value	200	200
Additional paid in capital	290,956	290,956
Series C Convertible Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Preferred stock value	385	385
Additional paid in capital	$ 500,507	$ 500,507

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	950,000,000	950,000,000
Common stock, shares issued	387,894,033	362,541,528
Common stock, shares outstanding	387,894,033	362,541,528
Series A Convertible Preferred Stock [Member]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	2,071,007	2,071,007
Preferred stock, shares outstanding	2,071,007	2,071,007
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	200,363	200,363
Preferred stock, shares outstanding	200,363	200,363
Series C Convertible Preferred Stock [Member]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	385,302	385,302
Preferred stock, shares outstanding	385,302	385,302

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues, net	$ 19,500	$ 36,499
Cost of Goods Sold	(25,536)	(28,779)
Gross (loss) profit	(6,036)	7,720
OPERATING EXPENSE
Professional fees, including stock-based compensation	1,606,923	1,755,316
Payroll expense	281,716	275,240
Research and development expense	732,698	343,802
General and administrative expense	165,773	151,111
Total Operating Expenses	2,787,110	2,525,469
OPERATING LOSS	(2,793,146)	(2,517,749)
NON-OPERATING INCOME (EXPENSE)
Interest income	49,577
Loss on issuance of shares	(151,184)
Gain on debt extinguishment		47,588
Total Non-Operating Income (Expense)	(101,607)	47,588
NET LOSS BEFORE PROVISION FOR INCOME TAXES	(2,894,753)	(2,470,161)
Provision for income taxes
NET LOSS	$ (2,894,753)	$ (2,470,161)
Net loss per share - basic	$ (0.01)	$ (0.01)
Net loss per share - diluted	$ (0.01)	$ (0.01)
Weighted average common shares outstanding - basic	368,805,214	351,425,912
Weighted average common shares outstanding - diluted	368,805,214	351,425,912

Statement of Changes in Stockho

Statement of Changes in Stockholders' Equity - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Additional Paid-In Capital - Series A Preferred [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member] Additional Paid-In Capital - Series B Preferred [Member]	Preferred Stock [Member] Series C Preferred Stock [Member]	Preferred Stock [Member] Additional Paid-In Capital - Series C Preferred [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021	$ 2,071	$ 8,842,458	$ 200	$ 290,956	$ 385	$ 500,507	$ 343,531	$ 68,573,142	$ (77,085,867)	$ 1,467,383
Balance, shares at Dec. 31, 2021	2,071,007		200,363		385,302		343,530,678
Cash							$ 15,000	1,185,000		1,200,000
Cash, shares							15,000,000
Accounts payable							$ 984	48,258		49,242
Accounts payable, shares							984,840
RSUs
RSUs, shares
Fractional adjustment
Fractional adjustment, shares							(90)
Services							$ 76	4,804		4,880
Services, shares							76,250
Warrant exercises and exchanges							$ 2,950	(2,950)
Warrant exercises and exchanges, shares							2,949,850
Warrants purchased for cash								20,000		20,000
RSUs granted to consultants that have vested								1,389,700		1,389,700
Net loss for the year									(2,470,161)	(2,470,161)
Balance at Dec. 31, 2022	$ 2,071	8,842,458	$ 200	290,956	$ 385	500,507	$ 362,541	71,217,954	(79,556,028)	1,661,044
Balance, shares at Dec. 31, 2022	2,071,007		200,363		385,302		362,541,528
Cash							$ 16,132	1,144,316		1,160,448
Cash, shares							16,132,000
Accounts payable							$ 500	27,950		28,450
Accounts payable, shares							500,000
RSUs							$ 4,000	(4,000)
RSUs, shares							4,000,000
Warrant exercises and exchanges							$ 4,721	146,463		151,184
Warrant exercises and exchanges, shares							4,720,505
Warrants purchased for cash								18,797		18,797
RSUs granted to consultants that have vested								1,239,950		1,239,950
Net loss for the year									(2,894,753)	(2,894,753)
Balance at Dec. 31, 2023	$ 2,071	$ 8,842,458	$ 200	$ 290,956	$ 385	$ 500,507	$ 387,894	$ 73,791,430	$ (82,450,781)	$ 1,365,120
Balance, shares at Dec. 31, 2023	2,071,007		200,363		385,302		387,894,033

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
CASH FLOW FROM OPERTING ACTIVIITES
Net loss	$ (2,894,753)	$ (2,470,161)
Adjustments to reconcile net loss to net cash used in operating activities
Common stock, stock options and warrants for services		4,880
RSUs issued for services	1,239,950	1,389,700
Loss on issuance of shares	151,184
(Gain) on conversion of debt		(47,588)
Changes in assets and liabilities
Accounts receivable	4,000	(11,000)
Prepaid expense and other assets	14,834	2,504
Accounts payable and accrued expense	191,762	11,607
Total adjustments	1,601,730	1,350,103
Net cash used in operating activities	(1,293,023)	(1,120,058)
CASH FLOWS FROM FINANCING ACTIVITES
Proceeds from common stock and warrants	1,179,245	1,220,000
Net cash provided by financing activities	1,179,245	1,220,000
NET (DECREASE) INCREASE IN CASH	(113,778)	99,942
CASH - BEGINNING OF YEAR	1,706,065	1,606,123
CASH - END OF YEAR	1,592,287	1,706,065
CASH PAID DURING THE PERIOD FOR:
Interest expense
Income taxes
SUPPLEMENTAL INFORMATION - NON-CASH INVESTING AND FINANCING ACTIVITIES:
Common stock issued in cashless exercise of warrants	4,721	2,950
RSUs vested into common stock	4,000
Accounts payable converted into shares of common stock	$ 28,450	$ 49,242

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure [Table]
Net Income (Loss) Attributable to Parent	$ (2,894,753)	$ (2,470,161)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2023
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

BASIS OF PRESENTATION AND SIGNI

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	NOTE 1: BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Business Overview The Company was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (“ SMSC 950,000,000 0.001 20,000,000 0.001 Our principal place of business is located at 719 Jadwin Avenue, Richland, WA 99352. Our telephone number is (509) 736-4000. Our corporate website address is http://www.radiogel.com. Our common stock is currently quoted on the OTC Pink Marketplace under the symbol “RDGL.” The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 (“ Y-90 ™ In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel ™ FDA ® Based on the FDA’s recommendation, RadioGel ™ ® ® ® ™ ® ™ ® ™” ® ® IsoPet Solutions The Company’s IsoPet ® ® ® The dogs were treated for canine soft tissue sarcoma. Response evaluation criteria in solid tumors (“ RECIST EORTC The testing at the University of Missouri met its objective to demonstrate the safety of IsoPet ® ® The effectiveness of IsoPet ® ® The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel ™ ® USA U.S. ® GAAP Commencing in July 2019, the Company recognized its first commercial sale of IsoPet ® FASB ASC ASC 606 ® Our plan is to incorporate the data assembled from our work with Isopet ® ™ ™ ™ ™ Recently the Company modified its Indication for Use from skin cancel to cancerous tissue or solid tumors pathologically associated with locoregional papillary thyroid carcinoma and recurrent papillary thyroid carcinoma having discernable tumors associated with metastatic lymph nodes or extranodal disease in patients who are not surgical candidates or who have declined surgery, or patients who require post-surgical remnant ablation (for example, after prior incomplete radioiodine therapy). Papillary thyroid carcinoma belongs to the general class of head and neck tumors for which tumors are accessible by intraoperative direct needle injection. The Company’s Medical Advisory Board felt that demonstrating efficacy in clinical trials was much easier with this new indication. Intellectual Property Our original license with Battelle National Laboratory (the “ Battelle License Our RadioGel TM TM ® . We have filed for trademark protection for the term Precision Radionuclide Therapy TM. The Company received the Patent Cooperation Treaty (“ PCT ® Our patent team filed our particle patent in more than ten patent offices that collectively cover 63 countries throughout the world. We filed a continuation-in-part applications number 1774054 in the USA to expand the claims on our particle patent. The U.S. Patent office recently gave us the Notice of Allowance for our patent to produce our yttrium phosphate microparticles, U.S. Patent Application Serial No: 16-459,466. We also filed an amendment to correct the wording on our claims at make them consistent with the USE claims. Ref: 4207-0005; European Patent Application NO. 20 834 229.5; VIVOS INC; Our Ref: FS/53791. We filed a hydrogel utility patent in the USA (16309:17/943,311) and internationally (16389:PCT/US22/4374) based on the last 18 months of development work to optimize our hydrogel component. These include reducing the polymer production time and increasing the output by a factor of three. We have also further reduced the level of trace contaminants to be well below the FDA guidelines. We filed a provisional patent (Serial Number 63436562) to protect our innovative improvements in our shipping container, our vial shield, our syringe shield, and our Peltier chiller. Our objectives were to reduce shipping costs, decrease radiation exposure, and enhance sterility. These devices will be preferentially used at Mayo Clinics for human clinical studies at and our IsoPet regional treatment centers. The Company filed a utility patent in Q4 2023 for this therapy support equipment. We anticipate that Precision Radionuclide Therapy will become increasingly important in the future and expand to other isotope and other indications for use. Therefore, we filed an alternate particle utility patent (Serial number 18/152,137). We will focus our near-term effort on the Y-90 therapy, which we believe is the best beta emitter; however, we leveraged our hydrogel utility patent to incorporate other promising isotopes and compounds for a range of future applications. This includes gamma and alpha particle emitters. Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $ 2.5 The Company completed its reverse stock split which was approved by FINRA and went effective on June 28, 2019. The Company’s stock offering under Regulation A+ was qualified by the Securities and Exchange Commission (“ SEC Offering Statement 50,000,000 shares at a price of $ 0.10 per share, for a maximum offering of $ 5,000,000 (the “ Regulation A+ Offering 1,200,000 at $ 0.08 per share ( 15,000,000 shares) and sold 20,000,000 warrants for $ 20,000 . An amendment to the Offering Statement was filed and qualified in October 2022, to raise the remaining $ 3,800,000 of the original offering amount of $ 5,000,000 at a price of $ 0.08 3,200,000 0.064 1,179,245 was raised through the issuance of 16,132,000 shares of common stock and warrants to purchase 18,797,000 shares of common stock. The Company’s offerings undertaken pursuant to Regulation A+ have raised approximately $ 6,000,000 For the animal therapy market: ● Fund the effort to communicate the benefits of IsoPet® to the veterinary community and the pet parents. ● Conduct additional clinical studies to generate more data for the veterinary community ● Subsidize some IsoPet ® ● Assist new regional clinics with their license and certification training. For the human market: ● Enhance the pedigree of the Quality Management System. ● Complete the previously defined pre-clinical testing and additional testing on an animal model closely aligned with our revised indication for use. Report the results to the FDA in a pre-submission meeting. ● Use the feedback from that meeting to write the (Investigational Device Exemption (“ IDE Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities. The Company may require additional funding of approximately $ 5 Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, and clinical trials; (3) activate several regional clinics to administer IsoPet ® The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise), and any requirements for additional studies (which may possibly include clinical studies). Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be: (1) the timing of any approvals; (2) the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products; and (3) the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements, as well as proceeds to be raised from the Regulation A+ Offering. Following receipt of required regulatory approvals and necessary financing to fund our working capital requirements, the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for operations within the U.S.. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy. Long-term, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses. These long-term goals are subject to the Company: (1) receiving adequate funding; (2) receiving regulatory approval for RadioGel TM Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations. The Company’s headquarters are in Northeast Washington however there focus of the animal therapy market has been the Northwestern sector of the United States. The Company continues their marketing to the animal therapy market and attempt to increase the exposure to their product and generate revenue accordingly. As of December 31, 2023, the Company has $ 1,592,287 There is no guarantee that the Company will be able to raise additional funds or to do so at an advantageous price. The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Use of Estimates The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates. Financial Statement Reclassification Certain account balances from prior periods have been reclassified in these financial statements so as to conform to current period classifications. Cash Equivalents For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. The Company occasionally maintains cash balances in excess of the FDIC insured limit. The Company does not consider this risk to be material. Fair Value of Financial Instruments Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2023 and 2022, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820- Fair Value Measurement, established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis. Patents and Intellectual Property While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such 10 The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows. There have been no such capitalized costs in the years ended December 31, 2023 and 2022, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet ® Revenue Recognition In May 2014, the FASB issued Accounting Standard Update (“ ASU Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The Company recognized revenue as they (i) identified the contracts with each customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation. All revenue recognized in the years ended December 31, 2023 and 2022 relate to the procedures performed with respect to the IsoPet ® Loss Per Share The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive common stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the periods ended in the years ended December 31, 2023 and 2022, the basic earnings per share equals the diluted earnings per share. The following represent common stock equivalents that could be dilutive in the future as of December 31, 2023 and 2022, which include the following: SCHEDULE OF DILUTIVE EARNINGS PER SHARE December 31, 2023 December 31, 2022 Preferred stock 9,909,570 9,909,570 Restricted stock units 1,450,000 25,362,500 Common stock options 2,252,809 2,252,809 Common stock warrants 26,134,000 26,737,500 Total potential dilutive securities 39,746,379 64,762,379 Research and Development Costs Research and developments costs, including salaries, research materials, administrative costs and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed. The Company incurred $ 732,698 343,802 Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. During the years ended December 31, 2023 and 2022, the Company incurred nominal advertising and marketing costs. Contingencies In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of December 31, 2023 and 2022. Income Taxes To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition. The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the years ended December 31, 2023 and 2022. The Company did not have any deferred tax liability or asset on its balance sheets on December 31, 2023 and 2022. Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the years ended December 31, 2023 and 2022, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months. Stock-Based Compensation The Company recognizes compensation costs under FASB ASC Topic 718, Compensation – Stock Compensation and ASU 2018-07. Companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. Recent Accounting Pronouncements The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 2: RELATED PARTY TRANSACTIONS Preferred and Common Shares Issued to Officers and Directors In March 2022, the Chief Executive Officer exercised 75,000 22,266 76,250 4,880 In September 2023, the CEO advanced $ 10,000

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 3: STOCKHOLDERS’ EQUITY Common Stock The Company has 950,000,000 0.001 387,894,033 362,541,528 Preferred Stock As of December 31, 2023 and 2022, the Company has 20,000,000 0.001 On October 8, 2018 the Company created out of the shares of Preferred Stock, par value $ 0.001 On March 27, 2019 the Company created out of the shares of Preferred Stock, par value $ 0.001 5,000,000 Series A Convertible Preferred Stock (“Series A Convertible Preferred”) In June 2015, the Series A Certificate of Designation was filed with the Delaware Secretary of State to designate 2.5 2,500,000 5,000,000 Liquidation Preference 5.00 Dividends Conversion Series A Conversion Shares 4.00 In the event the Company completes an equity or equity-based public offering, registered with the SEC, resulting in gross proceeds to the Company totaling at least $ 5.0 Redemption Subject to certain conditions set forth in the Series A Certificate of Designation, in the event of a Change of Control (defined in the Series A Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series A Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series A Convertible Preferred in cash at a price per share of Series A Convertible Preferred equal to 100 Voting Rights Holders of Series A Convertible Preferred are entitled to vote on all matters, together with the holders of common stock, and have the equivalent of five votes for every Series A Conversion Share issuable upon conversion of such holder’s outstanding shares of Series A Convertible Preferred. However, the Series A Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding common stock of the Company, and none of the rights of the Series A Convertible Preferred Liquidation Liquidation Certain Price and Share Adjustments (a) Stock Dividends and Stock Splits (b) Merger or Reorganization Series B Convertible Preferred Stock (“Series B Convertible Preferred”) In October 2018, the Series B Certificate of Designation was filed with the Delaware Secretary of State to designate 5.0 Liquidation Preference 1.00 Dividends Conversion Series B Conversion Shares 0.08 Redemption Subject to certain conditions set forth in the Series B Certificate of Designation, in the event of a Change of Control (defined in the Series B Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series B Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Convertible Preferred in cash at a price per share of Series B Convertible Preferred equal to 100 Voting Rights Holders of Series B Convertible Preferred are entitled to vote on all matters, together with the holders of common stock, and have the equivalent of two votes for every Series B Conversion Share issuable upon conversion of such holder’s outstanding shares of Series B Convertible Preferred. However, the Series B Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding common stock of the Company, and none of the rights of the Series A Convertible Preferred Liquidation Liquidation Certain Price and Share Adjustments (a) Stock Dividends and Stock Splits (b) Merger or Reorganization Series C Convertible Preferred Stock (“Series C Convertible Preferred”) In March 2019, the Series C Certificate of Designation was filed with the Delaware Secretary of State to designate 5.0 million shares of our preferred stock as Series C Convertible Preferred. The following summarizes the current rights and preferences of the Series C Convertible Preferred: Liquidation Preference 1.00 Dividends Conversion Series C Conversion Shares 0.08 The Series C Convertible Preferred will only be convertible at any time after the date that the Company shall have amended its Certificate of Incorporation to increase the number of shares of common stock authorized for issuance thereunder or effect a reverse stock split of the outstanding shares of common stock by a sufficient amount to permit the conversion of all Series C Convertible Preferred into shares of common stock (“ Authorized Share Approval Initial Convertibility Date Conversion Rights Redemption Subject to certain conditions set forth in the Series C Certificate of Designation, in the event of a Change of Control (defined in the Series C Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series C Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series C Convertible Preferred in cash at a price per share of Series C Convertible Preferred equal to 100 Voting Rights Liquidation Liquidation Certain Price and Share Adjustments ( a) Stock Dividends and Stock Splits (b) Merger or Reorganization Common and Preferred Stock Issuances – 2023 In April 2023, the Company issued 8,000,000 2,665,000 8,000,000 640,000 10,665 In October 2023, the Company issued 2,221,505 2,132,000 In December 2023, the Company issued: (1) 500,000 28,450 8,132,000 8,132,000 528,580 2,499,000 4,998,000 10,002,000 4,000,000 4,00,000 151,184 Common and Preferred Stock Issuances - 2022 In March 2022, the Company issued 299,577 shares of common stock in the cashless exercise of warrants to purchase 825,000 76,250 shares of common stock to its Chief Executive Officer for services rendered valued at $ 4,880 . In June 2022, there was a fractional adjustment recorded for 90 shares of common stock. On July 7, 2022, the Company sold 15,000,000 1,200,000 20,000,000 20,000 In September 2022, the Company issued 984,840 49,242

COMMON STOCK OPTIONS, WARRANTS

COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS	NOTE 4: COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS Common Stock Options The Company recognizes in the financial statements compensation related to all stock-based awards, including stock options and warrants, based on their estimated grant-date fair value. The Company has estimated expected forfeitures and is recognizing compensation expense only for those awards expected to vest. All compensation is recognized by the time the award vests. The following schedule summarizes the changes in the Company’s stock options: SCHEDULE OF CHANGES IN STOCK OPTION Weighted Weighted Options Outstanding Average Average Number Of Shares Exercise Price Per Share Remaining Aggregate Exercise Balance at December 31, 2021 2,252,809 $ 0.024 0.04 7.70 $ 83,992 $ 0.04 Options granted - $ - - $ - Options exercised - $ - - $ - Options expired/canceled - $ - - $ - Balance at December 31, 2022 2,252,809 $ 0.024 0.04 6.70 $ 16,032 $ 0.04 Exercisable at December 31, 2022 2,252,809 $ 0.024 0.04 6.70 $ 16,032 $ 0.04 Balance at December 31, 2022 2,252,809 $ 0.024 0.04 6.70 $ 16,032 $ 0.04 Options granted - $ - - $ - Options exercised - $ - - $ - Options expired/canceled - $ - - $ - Balance at December 31, 2023 2,252,809 $ 0.024 0.04 5.70 $ 78,886 $ 0.04 Exercisable at December 31, 2023 2,252,809 $ 0.024 0.04 5.70 $ 78,886 $ 0.04 During the years ended December 31, 2023 and 2022, the Company recognized $ 0 0 Common Stock Warrants The following schedule summarizes the changes in the Company’s stock warrants: SCHEDULE OF CHANGES IN STOCK WARRANTS Warrants Outstanding Weighted Average Weighted Average Number Of Shares Exercise Price Per Share Remaining Contractual Life Aggregate Intrinsic Value Exercise Price Per Share Balance at December 31, 2021 31,862,500 $ 0.04 0.10 1.02 $ 538,875 $ 0.07 Warrants granted 20,000,000 $ 0.01 0.08 2.50 $ 0.0725 Warrants exercised (4,158,333 ) $ - - $ Warrants expired/cancelled (20,966,667 ) $ - - $ Balance at December 31, 2022 26,737,500 $ 0.08 0.10 1.52 $ - $ 0.09 Exercisable at December 31, 2022 26,737,500 $ 0.06 0.10 1.52 $ - $ 0.09 Warrants granted 28,799,000 $ 0.0827 - - $ - Warrants redeemed (500,000 ) $ - - - $ - Warrants exercised (7,663,000 ) $ - - - $ - Warrants exchanged (10,002,000 ) $ - - - $ - Warrants expired/cancelled (11,237,500 ) $ - - - $ - Balance at December 31, 2023 26,134,000 $ 0.06 0.10 3.54 $ - $ 0.0827 Exercisable at December 31, 2023 26,134,000 $ 0.06 0.10 3.54 $ - $ 0.0827 Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each option/warrant is estimated using the Black-Scholes valuation model. In the years ended 2023 and 2022 all warrants issued were issued pursuant to the Regulation A+ Offering, and are included in equity. The following assumptions were used for the periods as follows: SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT Year Ended Year Ended December 31, 2023 December 31, 2022 Expected term - .5 3 Expected volatility - % 66 % Expected dividend yield - - Risk-free interest rate - % 3 % In April and December 2023, the Company sold warrants to purchase 18,797,000 18,797 10,002,000 10,002,000 2,499,000 7,663,000 11,237,500 500,000 In March 2022 the Company issued 299,577 825,000 1,000,000 On July 7, 2022, the Company sold 15,000,000 1,200,000 20,000,000 20,000 Restricted Stock Units The following schedule summarizes the changes in the Company’s restricted stock units (“ RSUs SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS Number Weighted Average Of Grant Date Shares Fair Value Balance at December 31, 2021 25,262,500 $ 0.08 RSU’s granted 100,000 $ 0.082 RSU’s vested (15,100,000 ) $ - RSU’s forfeited - $ - Balance at December 31, 2022 10,262,500 $ 0.08 RSUs forfeited (262,500 ) RSUs granted 6,900,000 $ 0.068 RSUs vested (15,450,000 ) $ - Balance at December 31, 2023 1,450,000 $ 0.09 During the years ended December 31, 2023 and 2022, the Company recognized $ 1,239,950 1,389,700 131,950 On February 3, 2022 and May 3, 2022, 10,000,000 900,000 100,000 8,200 On May 1, 2023, the Company granted 2,900,000 25 25 25 25 263,900 On August 4, 2023, the Chief Executive Officer rescinded 1,012,500 750,000 In December 2023, the Company granted 4,000,000 208,000

COMMITMENT

COMMITMENT	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENT	NOTE 5: COMMITMENT On June 4, 2019, the Company entered into an Executive Employment Agreement (“ Employment Agreement The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. The Company on December 31, 2020 extended this agreement through December 31, 2021 while renegotiating terms of a new Employment Agreement. On May 3, 2021, the Company and the Chief Executive Officer agreed the terms of a new Employment Agreement with an effective date of January 1, 2021 that has a term of three years and expired December 31, 2023. The Company renewed the Employment Agreement for a term of two years expiring December 31, 2025 . Under the terms of the Employment Agreement effective January 1, 2024, the Company shall pay to Dr. Korenko a base compensation of $ 295,500 10,000 20,000,000 two

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 6: INCOME TAXES Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Net deferred tax assets consist of the following components as of December 31, 2023 and 2022: SCHEDULE OF NET DEFERRED TAX ASSETS December 31, 2023 December 31, 2022 Deferred tax assets: Net operating loss carryover $ 6,840,000 $ 6,500,000 Capital Loss Carryover 3,400 3,400 Valuation allowance (6,843,400 ) (6,503,400 ) Net deferred tax asset $ - $ - The income tax provision differs from the amount of income tax determined by applying the U.S. Federal income tax rate to pretax income from continuing operations for the years ended December 31, 2023 and 2022 due to the following: SCHEDULE OF FEDERAL INCOME TAX RATE December 31, 2023 December 31, 2022 Book income (loss) $ (607,900 ) $ (518,700 ) Forgiveness of debt - - Depreciation (1,100 ) (1,100 ) Related party accrual - - Stock for services 260,400 291,800 Other non-deductible expense 6,300 10,500 Valuation allowance 342,300 217,500 Income tax expense $ - $ - At December 31, 2023, the Company had net operating loss carryforwards of approximately $ 32,585,800 ASC Topic 740 – Income Taxes (“ ASC 740 The Company includes interest and penalties arising from the underpayment of income taxes in the statements of operations in the provision for income taxes. As of December 31, 2023, the Company had no The Company files income tax returns in the U.S. federal jurisdiction. The Company is located in the state of Washington and Washington state does not require the filing of income taxes. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2017.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 7: SUBSEQUENT EVENTS From January 1, 2024 through the date of filing, the Company issued 2,000,000 2,000,000 128,000 The Chief Executive Officer entered into the Employment Agreement with the Company for two years 20,000,000 two

BASIS OF PRESENTATION AND SIG_2

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Business Overview	Business Overview The Company was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (“ SMSC 950,000,000 0.001 20,000,000 0.001 Our principal place of business is located at 719 Jadwin Avenue, Richland, WA 99352. Our telephone number is (509) 736-4000. Our corporate website address is http://www.radiogel.com. Our common stock is currently quoted on the OTC Pink Marketplace under the symbol “RDGL.” The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 (“ Y-90 ™ In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel ™ FDA ® Based on the FDA’s recommendation, RadioGel ™ ® ® ® ™ ® ™ ® ™” ® ®
IsoPet Solutions	IsoPet Solutions The Company’s IsoPet ® ® ® The dogs were treated for canine soft tissue sarcoma. Response evaluation criteria in solid tumors (“ RECIST EORTC The testing at the University of Missouri met its objective to demonstrate the safety of IsoPet ® ® The effectiveness of IsoPet ® ® The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel ™ ® USA U.S. ® GAAP Commencing in July 2019, the Company recognized its first commercial sale of IsoPet ® FASB ASC ASC 606 ® Our plan is to incorporate the data assembled from our work with Isopet ® ™ ™ ™ ™ Recently the Company modified its Indication for Use from skin cancel to cancerous tissue or solid tumors pathologically associated with locoregional papillary thyroid carcinoma and recurrent papillary thyroid carcinoma having discernable tumors associated with metastatic lymph nodes or extranodal disease in patients who are not surgical candidates or who have declined surgery, or patients who require post-surgical remnant ablation (for example, after prior incomplete radioiodine therapy). Papillary thyroid carcinoma belongs to the general class of head and neck tumors for which tumors are accessible by intraoperative direct needle injection. The Company’s Medical Advisory Board felt that demonstrating efficacy in clinical trials was much easier with this new indication.
Intellectual Property	Intellectual Property Our original license with Battelle National Laboratory (the “ Battelle License Our RadioGel TM TM ® . We have filed for trademark protection for the term Precision Radionuclide Therapy TM. The Company received the Patent Cooperation Treaty (“ PCT ® Our patent team filed our particle patent in more than ten patent offices that collectively cover 63 countries throughout the world. We filed a continuation-in-part applications number 1774054 in the USA to expand the claims on our particle patent. The U.S. Patent office recently gave us the Notice of Allowance for our patent to produce our yttrium phosphate microparticles, U.S. Patent Application Serial No: 16-459,466. We also filed an amendment to correct the wording on our claims at make them consistent with the USE claims. Ref: 4207-0005; European Patent Application NO. 20 834 229.5; VIVOS INC; Our Ref: FS/53791. We filed a hydrogel utility patent in the USA (16309:17/943,311) and internationally (16389:PCT/US22/4374) based on the last 18 months of development work to optimize our hydrogel component. These include reducing the polymer production time and increasing the output by a factor of three. We have also further reduced the level of trace contaminants to be well below the FDA guidelines. We filed a provisional patent (Serial Number 63436562) to protect our innovative improvements in our shipping container, our vial shield, our syringe shield, and our Peltier chiller. Our objectives were to reduce shipping costs, decrease radiation exposure, and enhance sterility. These devices will be preferentially used at Mayo Clinics for human clinical studies at and our IsoPet regional treatment centers. The Company filed a utility patent in Q4 2023 for this therapy support equipment. We anticipate that Precision Radionuclide Therapy will become increasingly important in the future and expand to other isotope and other indications for use. Therefore, we filed an alternate particle utility patent (Serial number 18/152,137). We will focus our near-term effort on the Y-90 therapy, which we believe is the best beta emitter; however, we leveraged our hydrogel utility patent to incorporate other promising isotopes and compounds for a range of future applications. This includes gamma and alpha particle emitters.
Going Concern	Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $ 2.5 The Company completed its reverse stock split which was approved by FINRA and went effective on June 28, 2019. The Company’s stock offering under Regulation A+ was qualified by the Securities and Exchange Commission (“ SEC Offering Statement 50,000,000 shares at a price of $ 0.10 per share, for a maximum offering of $ 5,000,000 (the “ Regulation A+ Offering 1,200,000 at $ 0.08 per share ( 15,000,000 shares) and sold 20,000,000 warrants for $ 20,000 . An amendment to the Offering Statement was filed and qualified in October 2022, to raise the remaining $ 3,800,000 of the original offering amount of $ 5,000,000 at a price of $ 0.08 3,200,000 0.064 1,179,245 was raised through the issuance of 16,132,000 shares of common stock and warrants to purchase 18,797,000 shares of common stock. The Company’s offerings undertaken pursuant to Regulation A+ have raised approximately $ 6,000,000 For the animal therapy market: ● Fund the effort to communicate the benefits of IsoPet® to the veterinary community and the pet parents. ● Conduct additional clinical studies to generate more data for the veterinary community ● Subsidize some IsoPet ® ● Assist new regional clinics with their license and certification training. For the human market: ● Enhance the pedigree of the Quality Management System. ● Complete the previously defined pre-clinical testing and additional testing on an animal model closely aligned with our revised indication for use. Report the results to the FDA in a pre-submission meeting. ● Use the feedback from that meeting to write the (Investigational Device Exemption (“ IDE Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities. The Company may require additional funding of approximately $ 5 Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, and clinical trials; (3) activate several regional clinics to administer IsoPet ® The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise), and any requirements for additional studies (which may possibly include clinical studies). Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be: (1) the timing of any approvals; (2) the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products; and (3) the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements, as well as proceeds to be raised from the Regulation A+ Offering. Following receipt of required regulatory approvals and necessary financing to fund our working capital requirements, the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for operations within the U.S.. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy. Long-term, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses. These long-term goals are subject to the Company: (1) receiving adequate funding; (2) receiving regulatory approval for RadioGel TM Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations. The Company’s headquarters are in Northeast Washington however there focus of the animal therapy market has been the Northwestern sector of the United States. The Company continues their marketing to the animal therapy market and attempt to increase the exposure to their product and generate revenue accordingly. As of December 31, 2023, the Company has $ 1,592,287 There is no guarantee that the Company will be able to raise additional funds or to do so at an advantageous price. The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.
Financial Statement Reclassification	Financial Statement Reclassification Certain account balances from prior periods have been reclassified in these financial statements so as to conform to current period classifications.
Cash Equivalents	Cash Equivalents For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. The Company occasionally maintains cash balances in excess of the FDIC insured limit. The Company does not consider this risk to be material.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2023 and 2022, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820- Fair Value Measurement, established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis.
Patents and Intellectual Property	Patents and Intellectual Property While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such 10 The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows. There have been no such capitalized costs in the years ended December 31, 2023 and 2022, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet ®
Revenue Recognition	Revenue Recognition In May 2014, the FASB issued Accounting Standard Update (“ ASU Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The Company recognized revenue as they (i) identified the contracts with each customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation. All revenue recognized in the years ended December 31, 2023 and 2022 relate to the procedures performed with respect to the IsoPet ®
Loss Per Share	Loss Per Share The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive common stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the periods ended in the years ended December 31, 2023 and 2022, the basic earnings per share equals the diluted earnings per share. The following represent common stock equivalents that could be dilutive in the future as of December 31, 2023 and 2022, which include the following: SCHEDULE OF DILUTIVE EARNINGS PER SHARE December 31, 2023 December 31, 2022 Preferred stock 9,909,570 9,909,570 Restricted stock units 1,450,000 25,362,500 Common stock options 2,252,809 2,252,809 Common stock warrants 26,134,000 26,737,500 Total potential dilutive securities 39,746,379 64,762,379
Research and Development Costs	Research and Development Costs Research and developments costs, including salaries, research materials, administrative costs and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed. The Company incurred $ 732,698 343,802
Advertising and Marketing Costs	Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. During the years ended December 31, 2023 and 2022, the Company incurred nominal advertising and marketing costs.
Contingencies	Contingencies In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of December 31, 2023 and 2022.
Income Taxes	Income Taxes To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition. The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the years ended December 31, 2023 and 2022. The Company did not have any deferred tax liability or asset on its balance sheets on December 31, 2023 and 2022. Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the years ended December 31, 2023 and 2022, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months.
Stock-Based Compensation	Stock-Based Compensation The Company recognizes compensation costs under FASB ASC Topic 718, Compensation – Stock Compensation and ASU 2018-07. Companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

BASIS OF PRESENTATION AND SIG_3

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
SCHEDULE OF DILUTIVE EARNINGS PER SHARE	The following represent common stock equivalents that could be dilutive in the future as of December 31, 2023 and 2022, which include the following: SCHEDULE OF DILUTIVE EARNINGS PER SHARE December 31, 2023 December 31, 2022 Preferred stock 9,909,570 9,909,570 Restricted stock units 1,450,000 25,362,500 Common stock options 2,252,809 2,252,809 Common stock warrants 26,134,000 26,737,500 Total potential dilutive securities 39,746,379 64,762,379

COMMON STOCK OPTIONS, WARRANT_2

COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
SCHEDULE OF CHANGES IN STOCK OPTION	The following schedule summarizes the changes in the Company’s stock options: SCHEDULE OF CHANGES IN STOCK OPTION Weighted Weighted Options Outstanding Average Average Number Of Shares Exercise Price Per Share Remaining Aggregate Exercise Balance at December 31, 2021 2,252,809 $ 0.024 0.04 7.70 $ 83,992 $ 0.04 Options granted - $ - - $ - Options exercised - $ - - $ - Options expired/canceled - $ - - $ - Balance at December 31, 2022 2,252,809 $ 0.024 0.04 6.70 $ 16,032 $ 0.04 Exercisable at December 31, 2022 2,252,809 $ 0.024 0.04 6.70 $ 16,032 $ 0.04 Balance at December 31, 2022 2,252,809 $ 0.024 0.04 6.70 $ 16,032 $ 0.04 Options granted - $ - - $ - Options exercised - $ - - $ - Options expired/canceled - $ - - $ - Balance at December 31, 2023 2,252,809 $ 0.024 0.04 5.70 $ 78,886 $ 0.04 Exercisable at December 31, 2023 2,252,809 $ 0.024 0.04 5.70 $ 78,886 $ 0.04
SCHEDULE OF CHANGES IN STOCK WARRANTS	The following schedule summarizes the changes in the Company’s stock warrants: SCHEDULE OF CHANGES IN STOCK WARRANTS Warrants Outstanding Weighted Average Weighted Average Number Of Shares Exercise Price Per Share Remaining Contractual Life Aggregate Intrinsic Value Exercise Price Per Share Balance at December 31, 2021 31,862,500 $ 0.04 0.10 1.02 $ 538,875 $ 0.07 Warrants granted 20,000,000 $ 0.01 0.08 2.50 $ 0.0725 Warrants exercised (4,158,333 ) $ - - $ Warrants expired/cancelled (20,966,667 ) $ - - $ Balance at December 31, 2022 26,737,500 $ 0.08 0.10 1.52 $ - $ 0.09 Exercisable at December 31, 2022 26,737,500 $ 0.06 0.10 1.52 $ - $ 0.09 Warrants granted 28,799,000 $ 0.0827 - - $ - Warrants redeemed (500,000 ) $ - - - $ - Warrants exercised (7,663,000 ) $ - - - $ - Warrants exchanged (10,002,000 ) $ - - - $ - Warrants expired/cancelled (11,237,500 ) $ - - - $ - Balance at December 31, 2023 26,134,000 $ 0.06 0.10 3.54 $ - $ 0.0827 Exercisable at December 31, 2023 26,134,000 $ 0.06 0.10 3.54 $ - $ 0.0827
SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT	SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT Year Ended Year Ended December 31, 2023 December 31, 2022 Expected term - .5 3 Expected volatility - % 66 % Expected dividend yield - - Risk-free interest rate - % 3 %
SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS	The following schedule summarizes the changes in the Company’s restricted stock units (“ RSUs SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS Number Weighted Average Of Grant Date Shares Fair Value Balance at December 31, 2021 25,262,500 $ 0.08 RSU’s granted 100,000 $ 0.082 RSU’s vested (15,100,000 ) $ - RSU’s forfeited - $ - Balance at December 31, 2022 10,262,500 $ 0.08 RSUs forfeited (262,500 ) RSUs granted 6,900,000 $ 0.068 RSUs vested (15,450,000 ) $ - Balance at December 31, 2023 1,450,000 $ 0.09

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
SCHEDULE OF NET DEFERRED TAX ASSETS	Net deferred tax assets consist of the following components as of December 31, 2023 and 2022: SCHEDULE OF NET DEFERRED TAX ASSETS December 31, 2023 December 31, 2022 Deferred tax assets: Net operating loss carryover $ 6,840,000 $ 6,500,000 Capital Loss Carryover 3,400 3,400 Valuation allowance (6,843,400 ) (6,503,400 ) Net deferred tax asset $ - $ -
SCHEDULE OF FEDERAL INCOME TAX RATE	The income tax provision differs from the amount of income tax determined by applying the U.S. Federal income tax rate to pretax income from continuing operations for the years ended December 31, 2023 and 2022 due to the following: SCHEDULE OF FEDERAL INCOME TAX RATE December 31, 2023 December 31, 2022 Book income (loss) $ (607,900 ) $ (518,700 ) Forgiveness of debt - - Depreciation (1,100 ) (1,100 ) Related party accrual - - Stock for services 260,400 291,800 Other non-deductible expense 6,300 10,500 Valuation allowance 342,300 217,500 Income tax expense $ - $ -

SCHEDULE OF DILUTIVE EARNINGS P

SCHEDULE OF DILUTIVE EARNINGS PER SHARE (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	39,746,379	64,762,379
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	9,909,570	9,909,570
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	1,450,000	25,362,500
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	2,252,809	2,252,809
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	26,134,000	26,737,500

BASIS OF PRESENTATION AND SIG_4

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)				1 Months Ended	12 Months Ended
	Oct. 31, 2022	Jul. 31, 2022	Sep. 15, 2021	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 01, 2023	Oct. 30, 2022	Jul. 07, 2022
Property, Plant and Equipment [Line Items]
Common stock, shares authorized				950,000,000	950,000,000	950,000,000
Common stock, par value				$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized				20,000,000	20,000,000	20,000,000
Preferred stock, par value				$ 0.001	$ 0.001	$ 0.001
Current operation activities					$ 2,500,000
Number of shares issued		15,000,000	50,000,000
Share price		$ 0.08	$ 0.10				$ 0.064	$ 0.08
Number of shares issued	$ 5,000,000	$ 1,200,000	$ 5,000,000		$ 1,160,448	$ 1,200,000
Number of warrants purchase		20,000,000		18,797,000	18,797,000
Warrantys outstanding		$ 20,000							$ 20,000
Number of shares issued	$ 3,800,000			$ 3,200,000
Common Stocks, Including Additional Paid in Capital				1,179,245	$ 1,179,245
Offering term					Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, and clinical trials; (3) activate several regional clinics to administer IsoPet® across the county; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States. The proceeds to be raised from the Regulation A+ Offering will be used to continue to fund this development.
Cash on hand				$ 1,592,287	$ 1,592,287
Economic life of the patent				10 years	10 years
Research and development costs					$ 732,698	$ 343,802
Brachytherapy Product Line [Member]
Property, Plant and Equipment [Line Items]
Current operation activities					5,000,000
Maximum [Member]
Property, Plant and Equipment [Line Items]
Proceeds from stock offering					$ 6,000,000
Common Stock [Member]
Property, Plant and Equipment [Line Items]
Number of shares issued					16,132,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2022	Sep. 30, 2023
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Stock issued for services, value		$ 4,880
Common Stock [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Stock issued for services, shares		76,250
Stock issued for services, value		$ 76
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Warrants exercised shares	75,000
Advance from officer			$ 10,000
Chief Executive Officer [Member] | Common Stock [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Conversion of stock	22,266
Stock issued for services, shares	76,250
Stock issued for services, value	$ 4,880

SCHEDULE OF CHANGES IN STOCK OP

SCHEDULE OF CHANGES IN STOCK OPTION (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Number of Options Outstanding Beginning Balance	2,252,809	2,252,809
Weighted Average Remaining Contractual Life (in years) Outstanding	5 years 8 months 12 days	6 years 8 months 12 days	7 years 8 months 12 days
Aggregate Intrinsic Value Outstanding Beginning	$ 16,032	$ 83,992
Weighted Average Exercise Price Per Share Outstanding Beginning	$ 0.04	$ 0.04
Number of Options granted
Exercise Price Per Share granted
Weighted Average Exercise Price Per Share Options granted
Number of Options exercised
Exercise Price Per Share exercised
Weighted Average Exercise Price Per Share Options exercised
Number of Options expired/cancelled
Exercise Price Per Share expired/cancelled
Weighted Average Exercise Price Per Share Options expired/cancelled
Number of Options Outstanding Ending Balance	2,252,809	2,252,809	2,252,809
Aggregate Intrinsic Value Outstanding Ending	$ 78,886	$ 16,032	$ 83,992
Weighted Average Exercise Price Per Share Outstanding Ending	$ 0.04	$ 0.04	$ 0.04
Number of Options Exercisable	2,252,809	2,252,809
Weighted Average Remaining Contractual Life (in years) Exercisable	5 years 8 months 12 days	6 years 8 months 12 days
Aggregate Intrinsic Value Exercisable	$ 78,886	$ 16,032
Weighted Average Exercise Price Per Share Exercisable	$ 0.04	$ 0.04
Minimum [Member]
Weighted Average Exercise Price Per Share Outstanding Beginning	0.024	0.024
Weighted Average Exercise Price Per Share Outstanding Ending	0.024	0.024	0.024
Exercise Price Per Share Exercisable	0.024	0.024
Maximum [Member]
Weighted Average Exercise Price Per Share Outstanding Beginning	0.04	0.04
Weighted Average Exercise Price Per Share Outstanding Ending	0.04	0.04	$ 0.04
Exercise Price Per Share Exercisable	$ 0.04	$ 0.04

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)					1 Months Ended									12 Months Ended
	Oct. 31, 2022	Jul. 31, 2022	Jul. 07, 2022	Sep. 15, 2021	Dec. 31, 2023	Oct. 31, 2023	Apr. 30, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Mar. 31, 2019	Oct. 31, 2018	Jun. 30, 2015	Dec. 31, 2023	Dec. 31, 2022	Mar. 27, 2019	Oct. 08, 2018	Mar. 31, 2016	Mar. 30, 2016
Class of Stock [Line Items]
Common stock, shares authorized					950,000,000									950,000,000	950,000,000
Common stock, par value					$ 0.001									$ 0.001	$ 0.001
Common stock, shares issued					387,894,033									387,894,033	362,541,528
Common stock, shares outstanding					387,894,033									387,894,033	362,541,528
Preferred stock shares authorized					20,000,000									20,000,000	20,000,000
Preferred stock, par value					$ 0.001									$ 0.001	$ 0.001
Number of shares issued		15,000,000		50,000,000
Number of shares issued, value	$ 5,000,000	$ 1,200,000		$ 5,000,000										$ 1,160,448	$ 1,200,000
Common stock additional offering					$ 1,179,245									$ 1,179,245
Warrants to purchase shares		20,000,000			18,797,000									18,797,000
Stock Issued During Period, Value, Issued for Services															$ 4,880
Functional adjustment shares									90
Warrants outstanding		$ 20,000	$ 20,000
Restricted Stock [Member]
Class of Stock [Line Items]
Number of shares vested					400,000
Accounts Payable [Member]
Class of Stock [Line Items]
Number of shares issued					500,000			984,840
Number of shares issued, value					$ 28,450			$ 49,242
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued			15,000,000		8,132,000	2,221,505	8,000,000			299,577				16,132,000	15,000,000
Number of shares issued, value			$ 1,200,000				$ 640,000							$ 16,132	$ 15,000
Proceeds from issuance of warrants							10,665
Common stock additional offering					$ 528,580									$ 528,580
Number of shares sold			15,000,000		2,499,000
Number of shares vested					4,000,000
Warrants to purchase shares										825,000
Stock Issued During Period, Shares, Issued for Services															76,250
Stock Issued During Period, Value, Issued for Services															$ 76
Number of shares issued, value			$ 1,200,000
Number of warrants sold			20,000,000
Common Stock [Member] | Chief Executive Officer [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services										76,250
Stock Issued During Period, Value, Issued for Services										$ 4,880
Warrant [Member]
Class of Stock [Line Items]
Number of shares issued					8,132,000
Proceeds from issuance of warrants					$ 18,797		$ 18,797
Warrants exercise shares						2,132,000				825,000
Number of shares sold					4,998,000
Gain loss on exchange					$ 151,184
Warrants to purchase shares			20,000,000
Warrants outstanding			$ 20,000
New Warrant [Member]
Class of Stock [Line Items]
Number of shares sold					10,002,000
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized					5,000,000							5,000,000		5,000,000	5,000,000
Preferred stock, par value																	$ 0.001
Preferred stock, liquidation preference per share												$ 1
Conversion price per share												$ 0.08
Preferred stock redemption, description												Subject to certain conditions set forth in the Series B Certificate of Designation, in the event of a Change of Control (defined in the Series B Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series B Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Convertible Preferred in cash at a price per share of Series B Convertible Preferred equal to 100% of the Liquidation Preference
Redemption percentage												100%
Voting percentage												Holders of Series B Convertible Preferred are entitled to vote on all matters, together with the holders of common stock, and have the equivalent of two votes for every Series B Conversion Share issuable upon conversion of such holder’s outstanding shares of Series B Convertible Preferred. However, the Series B Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding common stock of the Company, and none of the rights of the Series A Convertible Preferred
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized					5,000,000									5,000,000	5,000,000	5,000,000
Preferred stock, par value																$ 0.001
Preferred stock, liquidation preference per share											$ 1
Conversion price per share											$ 0.08
Redemption percentage											100%
Voting percentage											Subject to certain conditions set forth in the Series C Certificate of Designation, in the event of a Change of Control (defined in the Series C Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series C Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series C Convertible Preferred in cash at a price per share of Series C Convertible Preferred equal to 100% of the Liquidation Preference
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized					5,000,000								2,500,000	5,000,000	5,000,000			5,000,000	2,500,000
Preferred stock, liquidation preference per share													$ 5
Conversion price per share													$ 4
Gross proceeds from preferred stock													$ 5,000,000
Preferred stock redemption, description													Subject to certain conditions set forth in the Series A Certificate of Designation, in the event of a Change of Control (defined in the Series A Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series A Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series A Convertible Preferred in cash at a price per share of Series A Convertible Preferred equal to 100% of the Liquidation Preference
Redemption percentage													100%
Voting percentage													Holders of Series A Convertible Preferred are entitled to vote on all matters, together with the holders of common stock, and have the equivalent of five votes for every Series A Conversion Share issuable upon conversion of such holder’s outstanding shares of Series A Convertible Preferred. However, the Series A Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding common stock of the Company, and none of the rights of the Series A Convertible Preferred
Series A Warrant [Member]
Class of Stock [Line Items]
Number of shares issued							2,665,000
Series B Warrant [Member]
Class of Stock [Line Items]
Number of shares issued							8,000,000

SCHEDULE OF CHANGES IN STOCK WA

SCHEDULE OF CHANGES IN STOCK WARRANTS (Details) - Warrant [Member] - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, Warrants Outstanding Beginning	26,737,500	31,862,500
Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning		1 year 7 days
Aggregate Intrinsic Value Outstanding Beginning		$ 538,875
Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning	$ 0.09	$ 0.07
Number of Shares, Warrants granted	28,799,000	20,000,000
Exercise Price Per Share Warrants granted	$ 0.0827
Weighted Average Remaining Contractual Life Warrants Outstanding, Warrants granted		2 years 6 months
Weighted Average Exercise Price Per Share Exercise Price Warrants granted		$ 0.0725
Number of Shares, Warrants exercised	(7,663,000)	(4,158,333)
Exercise Price Per Share Warrants exercised
Number of Shares, Warrants expired/cancelled	(11,237,500)	(20,966,667)
Exercise Price Per Share Warrants expired/cancelled
Weighted Average Remaining Contractual Life Warrants Outstanding Ending	3 years 6 months 14 days	1 year 6 months 7 days
Aggregate Intrinsic Value Outstanding Ending
Weighted Average Exercise Price Per Share Exercise Price Warrants Ending	$ 0.0827	$ 0.09
Number of Shares, Warrants Exercisable Beginning	26,737,500
Weighted Average Remaining Contractual Life Warrants Exercisable	3 years 6 months 14 days	1 year 6 months 7 days
Aggregate Intrinsic Value Exercisable Beginning
Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable Beginning	$ 0.09
Number of Shares, Warrants redeemed	(500,000)
Number of Shares, Warrants exchanged	(10,002,000)
Exercise Price Per Share Warrants exercised
Number of Shares, Warrants Outstanding Ending	26,134,000	26,737,500
Number of Shares, Warrants Exercisable Ending	26,134,000	26,737,500
Aggregate Intrinsic Value Exercisable
Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable	$ 0.0827	$ 0.09
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price Per Share Warrants Outstanding Beginning	0.08	0.04
Exercise Price Per Share Warrants granted		0.01
Exercise Price Per Share Exercisable Beginning	0.06
Exercise Price Per Share Warrants Exercisable Ending	0.06	0.08
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price Per Share Warrants Outstanding Beginning	0.10	0.10
Exercise Price Per Share Warrants granted		0.08
Exercise Price Per Share Exercisable Beginning	0.10
Exercise Price Per Share Warrants Exercisable Ending	$ 0.10	$ 0.10

SCHEDULE OF ASSUMPTIONS USED IN

SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Expected term
Expected volatility		66%
Expected dividend yield
Risk-free interest rate		3%
Minimum [Member]
Expected term		6 months
Maximum [Member]
Expected term		3 years

SCHEDULE OF CHANGES IN RESTRICT

SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS (Details) - Restricted Stock Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, RSU's Beginning balance	10,262,500	25,262,500
Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning	$ 0.08	$ 0.08
Number of Shares, RSU's granted	6,900,000	100,000
Weighted Average Grant Date Fair Value, RSU's granted	$ 0.068	$ 0.082
Number of Shares, RSU's vested	(15,450,000)	(15,100,000)
Weighted Average Grant Date Fair Value, RSU's vested
Number of Shares, RSU's forfeited	262,500
Weighted Average Grant Date Fair Value, RSU's forfeited
Number of Shares, RSU's forfeited	(262,500)
Number of Shares, RSU's Ending balance	1,450,000	10,262,500
Weighted Average Grant Date Fair Value, RSU's Outstanding Ending	$ 0.09	$ 0.08

COMMON STOCK OPTIONS, WARRANT_3

COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Details Narrative) - USD ($)													1 Months Ended					12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Aug. 04, 2023	May 01, 2023	Oct. 31, 2022	Jul. 31, 2022	Jul. 07, 2022	Jun. 01, 2022	May 03, 2022	Feb. 03, 2022	Sep. 15, 2021	Dec. 31, 2023	Oct. 31, 2023	Apr. 30, 2023	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold							15,000,000					50,000,000
Number of shares issued, value						$ 5,000,000	$ 1,200,000					$ 5,000,000						$ 1,160,448	$ 1,200,000
Warrants			18,797,000				20,000,000						18,797,000					18,797,000
Warrants and rights outstanding							$ 20,000	$ 20,000
Restricted stock expense vesting																		$ 1,239,950	$ 1,389,700
Restricted stock expenses yet to be recognized																		$ 131,950
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold																		28,799,000	20,000,000
Number of Shares, Warrants exchanged																		10,002,000
Number of warrant exercised																		7,663,000	4,158,333
Number of Shares, Warrants expired/cancelled																		11,237,500	20,966,667
Number of Shares, Warrants redeemed																		500,000
Restricted Stock Units (RSUs) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Restricted stock vested, value					$ 263,900
Number of restricted shares unit granted					2,900,000								4,000,000
Number of shares issued			25%		25%
Number of restricted shares unit granted, value													$ 208,000
Restricted Stock Units (RSUs) [Member] | Forecast [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued	25%	25%
Restricted Stock Units (RSUs) [Member] | Chief Executive Officer [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Restricted stock vested, shares				1,012,500						10,000,000	10,000,000
Restricted stock vested, value									$ 8,200	$ 900,000	$ 900,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares				750,000
Restricted Stock Units (RSUs) [Member] | Consultant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of restricted shares unit granted									100,000
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold													18,797,000		18,797,000
Number of shares issued, value													$ 18,797		$ 18,797
Number of warrant exercised														2,132,000			825,000
Number of shares sold													8,132,000
Warrants expired																1,000,000
Warrants								20,000,000
Warrants and rights outstanding								$ 20,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued, value															$ 10,665
Number of Shares, Warrants exchanged																		2,499,000
Number of shares sold								15,000,000					8,132,000	2,221,505	8,000,000		299,577	16,132,000	15,000,000
Number of shares issued, value								$ 1,200,000							$ 640,000			$ 16,132	$ 15,000
Warrants																	825,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares													4,000,000
Equity Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock based compensation																		$ 0	$ 0

COMMITMENT (Details Narrative)

COMMITMENT (Details Narrative) - Dr. Michael K. Korenko [Member] - USD ($)	Jan. 01, 2024	Jun. 04, 2019
Employment Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Agreement term description		The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. The Company on December 31, 2020 extended this agreement through December 31, 2021 while renegotiating terms of a new Employment Agreement. On May 3, 2021, the Company and the Chief Executive Officer agreed the terms of a new Employment Agreement with an effective date of January 1, 2021 that has a term of three years and expired December 31, 2023. The Company renewed the Employment Agreement for a term of two years expiring December 31, 2025
Employment Agreement [Member] | Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Compensation amount	$ 295,500
Discretionary bonus	$ 10,000
Restricted Stock Units (RSUs) [Member] | Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares granted	20,000,000
Vest period	2 years

SCHEDULE OF NET DEFERRED TAX AS

SCHEDULE OF NET DEFERRED TAX ASSETS (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Net operating loss carryover	$ 6,840,000	$ 6,500,000
Capital Loss Carryover	3,400	3,400
Valuation allowance	(6,843,400)	(6,503,400)
Net deferred tax asset

SCHEDULE OF FEDERAL INCOME TAX

SCHEDULE OF FEDERAL INCOME TAX RATE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Book income (loss)	$ (607,900)	$ (518,700)
Forgiveness of debt
Depreciation	(1,100)	(1,100)
Related party accrual
Stock for services	260,400	291,800
Other non-deductible expense	6,300	10,500
Valuation allowance	342,300	217,500
Income tax expense

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative)	Dec. 31, 2023 USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 32,585,800
Unrecognized tax positions accrued interest or penalties	$ 0

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)

1 Months Ended

2 Months Ended

12 Months Ended

Jan. 01, 2024

Oct. 31, 2022

Jul. 31, 2022

Jul. 07, 2022

Sep. 15, 2021

Dec. 31, 2023

Oct. 31, 2023

Apr. 30, 2023

Mar. 31, 2022

Feb. 29, 2024

Dec. 31, 2023

Dec. 31, 2022

Subsequent Event [Line Items]

Cash, shares

15,000,000

50,000,000

Number of shares issued

$ 5,000,000

$ 1,200,000

$ 5,000,000

$ 1,160,448

$ 1,200,000

Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member] | Dr. Michael K. Korenko [Member]

Subsequent Event [Line Items]

Terms of agreement

2 years

Shares granted

20,000,000

Vest period

2 years

Common Stock [Member]

Subsequent Event [Line Items]

Cash, shares

15,000,000

8,132,000

2,221,505

8,000,000

299,577

16,132,000

15,000,000

Number of shares issued

$ 1,200,000

$ 640,000

$ 16,132

$ 15,000

Common Stock [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Cash, shares

2,000,000

Warrant [Member]

Subsequent Event [Line Items]

Cash, shares

8,132,000

Warrant [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Cash, shares

2,000,000

Common Stock And Warrant [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Number of shares issued

$ 128,000